Mobile App-Based Infection Monitoring in Familial Mediterranean Fever
NCT07212764 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2025-12-03
Summary
Familial Mediterranean Fever (FMF) is an autoinflammatory disease characterized by recurrent episodes of fever, abdominal pain, and serositis. FMF attacks often present with fever and systemic symptoms resembling infectious diseases, making it challenging in clinical practice to distinguish between an attack and an infection. Moreover, infections are known to trigger FMF attacks; however, the number of prospective studies evaluating this association remains limited.
In the current literature, the frequency of attacks and triggering factors in FMF patients have mostly been assessed through retrospective chart reviews. Such methods are prone to incomplete or recall-based data regarding the onset of attacks and infection-related symptoms. With the growing availability of digital health applications, it has become possible to record disease symptoms in real time and on a regular basis, providing more reliable data for both clinicians and researchers.
The present study aims to prospectively evaluate the relationship between infections and disease flares in FMF patients by systematically recording infection symptoms and attack characteristics through a mobile application. This approach is intended to achieve a better understanding of the infection-flare association, improve patient management, and prevent unnecessary treatments. In addition, the feasibility of mobile application-based patient monitoring will be assessed, and its potential contribution to routine clinical practice will be explored.
Conditions
- Familial Mediterranean Fever (FMF )
- Infection
- Mobile Application
Interventions
- OTHER
-
mobile application
Patients will be instructed to record any symptoms suggestive of infectious diseases-such as fever, cough, nasal discharge, or myalgia-directly into the mobile application whenever they occur. The app will provide simple checklists and entry fields, allowing patients (or their caregivers) to promptly log these symptoms in real time. By systematically documenting infection-related manifestations alongside routine follow-up data, it will be possible to prospectively evaluate whether infectious episodes act as potential triggers for Familial Mediterranean Fever (FMF) attacks. The collected data will then be analyzed to determine temporal and clinical associations between infection symptoms and subsequent disease flares, thereby clarifying whether infections precipitate or overlap with FMF attacks.
Sponsors & Collaborators
-
Istanbul University
lead OTHER
Principal Investigators
-
Bengisu Menentoğlu · Istanbul University
Eligibility
- Min Age
- 8 Years
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-11-05
- Primary Completion
- 2026-03-15
- Completion
- 2026-07-15
Countries
- Turkey (Türkiye)
Study Locations
More Related Trials
-
Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients
NCT01075906 ·Status: COMPLETED ·Phase: PHASE1
-
Microbiological Diagnosis of Infectious Uveitis to Pathogenic Fastidious Germs
NCT02819206 ·Status: COMPLETED ·Phase: NA
-
Life Quality Study for PFAPA Patient
NCT02811705 ·Status: COMPLETED
-
Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation
NCT02175589 ·Status: UNKNOWN ·Phase: PHASE2
-
Granulocyte Transfusions in Hematological Patients With Febrile Neutropenia
NCT02544230 ·Status: COMPLETED
-
Journey of Patients With Vasculitis From First Symptom to Diagnosis
NCT03410290 ·Status: COMPLETED
-
Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine
NCT05092776 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Eosinophil and Anticoagulation in COVID-19 Patients
NCT04507282 ·Status: COMPLETED
-
Colchicine Levels in the Serum of FMF (Familial Mediterranean Fever) Patients
NCT03210610 ·Status: UNKNOWN
-
Establishment of an Early Warning Screening System for Hemophagocytic Lymphohistiocytosis a Multi-center, Prospective Study
NCT06614998 ·Status: RECRUITING
-
Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH
NCT04347460 ·Status: UNKNOWN
-
Reproductive Health in Men and Women With Vasculitis
NCT02176070 ·Status: COMPLETED
-
Role of Femoral Vein Wall Thickness and Inflammatory Markers in Patients With Behcet Disease
NCT06721234 ·Status: RECRUITING
-
Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy
NCT05894512 ·Status: COMPLETED
-
Vasculitis Illness Perception (VIP) Study
NCT02190916 ·Status: COMPLETED
-
Long-term Sequelae of COVID-19 (Myalgic Encephalomyelitis): An International Cross-Sectional Study
NCT05059184 ·Status: COMPLETED
-
Describe the Progression of Inflammatory Orbitopathy and the Biological Progression of Patients Receiving Second-line Treatment
NCT07117981 ·Status: RECRUITING
-
Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease
NCT03371095 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Glucocorticoids Plus Rituximab in Patients with Newly-Diagnosed or Relapsing IgA Vasculitis
NCT05329090 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Thrombophilia and Thrombosis in Behçet's Disease
NCT06451575 ·Status: RECRUITING
-
Plasma Soluble Urokinase Plasminogen Activator Receptor and Behçet's Disease .
NCT04105439 ·Status: UNKNOWN
-
Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome
NCT05845723 ·Status: RECRUITING ·Phase: PHASE2
-
MPA AUC Monitoring in Patients Receiving MMF for Diffuse Cutaneous or Pulmonary Involvement in Systemic Sclerosis
NCT04244916 ·Status: TERMINATED
-
Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
NCT00307671 ·Status: COMPLETED ·Phase: PHASE4
-
Role of Regulatory B Cells in Behçet's Disease
NCT04376411 ·Status: COMPLETED